Back to top
more

Mesa Laboratories (MLAB)

(Real Time Quote from BATS)

$104.20 USD

104.20
6,868

-2.42 (-2.27%)

Updated Apr 24, 2024 11:18 AM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

1-Strong Buy of 5 1        

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value F Growth F Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 38% (95 out of 252)

Industry: Medical - Instruments

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Best Value Stocks to Buy for April 8th

by Zacks Equity Research

SM and MLAB made it to the Zacks Rank #1 (Strong Buy) value stocks list on April 8, 2023.

Mesa Labs (MLAB) Lags Q3 Earnings and Revenue Estimates

by Zacks Equity Research

Mesa Labs (MLAB) delivered earnings and revenue surprises of -0.98% and 2.60%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?

Reasons to Add Integer Holdings (ITGR) to Your Portfolio Now

by Zacks Equity Research

Integer Holdings' (ITGR) research and product development activities and a solid foothold in the broader MedTech space raise optimism about the stock.

Rapid Micro Biosystems, Inc. (RPID) Reports Q3 Loss, Tops Revenue Estimates

by Zacks Equity Research

Rapid Micro Biosystems, Inc. (RPID) delivered earnings and revenue surprises of 3.12% and 11.22%, respectively, for the quarter ended September 2023. Do the numbers hold clues to what lies ahead for the stock?

Penumbra and Mesa Labs have been highlighted as Zacks Bull and Bear of the Day

by Zacks Equity Research

Penumbra and Mesa Labs are part of the Zacks Bull and Bear of the Day article.

Kevin Cook headshot

Bear of the Day: Mesa Labs (MLAB)

by Kevin Cook

Mesa diagnostics gains importance among big pharma so we want to watch this dip

Mesa Labs (MLAB) Surpasses Q1 Earnings Estimates

by Zacks Equity Research

Mesa Labs (MLAB) delivered earnings and revenue surprises of 5.99% and 2.32%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?

Mesa Labs (MLAB) Q4 Earnings and Revenues Miss Estimates

by Zacks Equity Research

Mesa Labs (MLAB) delivered earnings and revenue surprises of -2.02% and 3.20%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

ReWalk Robotics (RWLK) Reports Q1 Loss, Misses Revenue Estimates

by Zacks Equity Research

ReWalk (RWLK) delivered earnings and revenue surprises of 12.50% and 38.50%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

RxSight, Inc. (RXST) Reports Q1 Loss, Tops Revenue Estimates

by Zacks Equity Research

RxSight, Inc. (RXST) delivered earnings and revenue surprises of 19.23% and 7.20%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

Shockwave Medical (SWAV) Beats Q1 Earnings and Revenue Estimates

by Zacks Equity Research

Shockwave Medical (SWAV) delivered earnings and revenue surprises of 27.16% and 10.62%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

Paragon 28, Inc. (FNA) Reports Q1 Loss, Tops Revenue Estimates

by Zacks Equity Research

Paragon 28, Inc. (FNA) delivered earnings and revenue surprises of -10% and 3.53%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

Sensus Healthcare, Inc. (SRTS) Reports Q1 Loss, Misses Revenue Estimates

by Zacks Equity Research

Sensus Healthcare, Inc. (SRTS) delivered earnings and revenue surprises of -209.09% and 63.06%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

Mesa Labs (MLAB) Stock Sinks As Market Gains: What You Should Know

by Zacks Equity Research

Mesa Labs (MLAB) closed the most recent trading day at $171.42, moving -1.89% from the previous trading session.

Why Investors Need to Take Advantage of These 2 Medical Stocks Now

by Zacks Equity Research

The Zacks Earnings ESP is a great way to find potential earnings surprises. Why investors should take advantage now.

Is Mesa Labs (MLAB) a Solid Growth Stock? 3 Reasons to Think "Yes"

by Zacks Equity Research

Mesa Labs (MLAB) is well positioned to outperform the market, as it exhibits above-average growth in financials.

Mesa Labs (MLAB) Tops Q3 Earnings Estimates

by Zacks Equity Research

Mesa Labs (MLAB) delivered earnings and revenue surprises of 11.90% and 5.95%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

What's in the Cards for Mesa Laboratories' (MLAB) Q3 Earnings?

by Zacks Equity Research

Continued strength in Mesa Laboratories' (MLAB) Clinical Genomics segment is expected to have driven up Q3 sales.

Mesa Labs (MLAB) Outpaces Stock Market Gains: What You Should Know

by Zacks Equity Research

Mesa Labs (MLAB) closed at $193.27 in the latest trading session, marking a +0.56% move from the prior day.

Mesa Labs (MLAB) Gains As Market Dips: What You Should Know

by Zacks Equity Research

Mesa Labs (MLAB) closed at $193.84 in the latest trading session, marking a +0.96% move from the prior day.

Mesa Labs (MLAB) Outpaces Stock Market Gains: What You Should Know

by Zacks Equity Research

Mesa Labs (MLAB) closed at $190.51 in the latest trading session, marking a +0.93% move from the prior day.

Is Mesa Laboratories (MLAB) Outperforming Other Medical Stocks This Year?

by Zacks Equity Research

Here is how Mesa Labs (MLAB) and Cassava Sciences, Inc. (SAVA) have performed compared to their sector so far this year.

Mesa Labs (MLAB) Gains As Market Dips: What You Should Know

by Zacks Equity Research

Mesa Labs (MLAB) closed the most recent trading day at $178.79, moving +1.53% from the previous trading session.

Here's Why You Should Retain Glaukos (GKOS) in Your Portfolio

by Zacks Equity Research

Glaukos (GKOS) continues to benefit from a robust product portfolio and favorable clinical trial results.

Here's Why You Should Buy Cardinal Health (CAH) Stock Now

by Zacks Equity Research

Cardinal Health (CAH) continues to gain traction from the solid pharmaceutical segment and a diversified product portfolio. However, the cost of products continues to rise.